아이엠바이오로직스

493280KOSDAQSector: Pharma & Biotech

₩16,520▼ 3.39%Market cap ₩245.1BAs of Jul 21, 2026 close · updated once daily

Grade B63.2 ptsTop 26% of 2,523 stocks

Financial strength

79.8

Price attractiveness

44.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

ⓘ Growth momentum not rated — will be included automatically as data accumulates

Financial strength

79.8

How much debt does it carry relative to equity?

Debt-to-equity ratio

2.5%

✓ Above median · Top 1% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

7301.4%

✓ Above median · Top 1% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

2.6%

✓ Above median · Top 39.3% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

1.2%

✓ Above median · Top 39.6% in sector

Sector median -4.5%

Source filing: annual report (separate) — view original ↗

Price attractiveness

44.2

Is the price expensive relative to earnings?

P/E (price-to-earnings)

279.5x

✓ Above median · Top 40.4% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

3.34x

✗ Below median · Top 71.3% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15